MedTrace Logo

Intensified Dosing of Cellcept (Mycophenolate Mofetil) in Kidney Transplantation

NCT00943228 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-08-09

No results posted yet for this study

Summary

The primary objective of this study is to determine whether 4 grams daily of mycophenolate mofetil (MMF) results in a greater proportion of individuals adequately exposed as measured by drug levels (area under the curve of \> 40 mg\*hr/L).

Conditions

  • Acute Rejection of Renal Transplant

Interventions

DRUG

mycophenolate mofetil

High dose 4gms daily

Sponsors & Collaborators

  • Nova Scotia Health Authority

    lead OTHER

Principal Investigators

  • Bryce A Kiberd, MD · Dalhousie University

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00943228 on ClinicalTrials.gov